Many patients with a form of brain cancer called glioma have mutations in two genes that code for enzymes, IDH1 and IDH2. These changes result in increased levels of a compound called 2-hydroxyglutarate (2HG), seen in 80% of low- and intermediate-grade gliomas, and this biomarker can be detected using magnetic resonance spectroscopy (MRS). In a technical report published in Nature Medicine, researchers from University of Texas Southwestern Medical Center confirmed the technique's efficacy by analyzing tumors from 30 patients. They suggested that 2HG could be a valuable diagnostic and prognostic biomarker, as patients with this mutation tend to have better outcomes. Article | Abstract